Yes, Orenitram (oral treprostinil) is an appropriate option to add to tadalafil in this patient with PAH who is intolerant to ambrisentan.
Given that your patient is already on tadalafil monotherapy after ambrisentan intolerance, adding Orenitram represents a rational escalation strategy to achieve combination therapy targeting multiple pathophysiologic pathways in PAH. 1
Rationale for Adding Orenitram
Orenitram is FDA-approved for PAH (WHO Group 1) to delay disease progression and improve exercise capacity 1. The drug was studied predominantly in patients with WHO functional class II-III symptoms, making it appropriate for most ambulatory PAH patients 1.
Evidence for Prostacyclin Addition to PDE5 Inhibitors
The 2019 CHEST guidelines specifically address adding prostacyclin therapy (including oral treprostinil) to background therapy with PDE5 inhibitors and/or ERAs 2. While the FREEDOM-C2 trial showed only a modest non-significant improvement in 6-minute walk distance (median difference 10 meters, P=0.089) when adding oral treprostinil to background ERAs and/or PDE5Is, the guidelines note this study was limited by:
- High premature discontinuation rates
- Short treatment duration (16 weeks)
- Potential ceiling effect in patients already on multiple therapies 2
The guidelines state there is "insufficient evidence to make a recommendation for or against" adding oral treprostinil to background therapy, but this reflects the quality of available trial data rather than a contraindication to its use 2.
Practical Implementation Strategy
Starting Dose and Titration
- Start at 0.125 mg three times daily (TID) with food, approximately 8 hours apart OR 0.25 mg twice daily (BID) with food, approximately 12 hours apart 1
- Titrate by 0.125 mg TID or 0.25-0.5 mg BID no more frequently than every 3-4 days 1
- Target the highest tolerated dose up to a maximum of 120 mg daily 1
- Swallow tablets whole—never crush, split, or chew 1
Managing Common Side Effects
The ADAPT Registry provides critical real-world data on side effect management 3:
Early therapy (Months 1-5):
- 62% experience headache and diarrhea
- 40% experience nausea
By Month 6:
- 61% report headache improvement
- 44% report diarrhea improvement
- 70% report nausea improvement
Effective treatments include:
- Acetaminophen for headache
- Loperamide for diarrhea
- Ondansetron for nausea 3
Critical Pitfalls to Avoid
Never abruptly discontinue Orenitram—this can cause worsening PAH symptoms 1
If 2 or more doses are missed, contact the prescriber as dose adjustment may be needed 1
Avoid use if the patient has:
If taking strong CYP2C8 inhibitors (e.g., gemfibrozil), start at 0.125 mg BID with slower titration 1
Diverticulosis warning: The tablet shell may get stuck in diverticula 1
Dosing Optimization
Real-world data demonstrate that higher doses correlate with increased treatment benefit 3. Recent evidence shows:
- Patients transitioning from parenteral prostacyclins achieve higher total daily doses and persist longer on therapy compared to de novo patients 4
- Four times daily (QID) dosing may allow higher total daily doses with better tolerability compared to TID dosing in selected patients 5
- The proportion of patients initiating oral treprostinil has increased from 24% to 41% between 2017-2023, with mean initial doses rising from 6.0 to 8.9 mg TDD 4
Alternative Consideration
If your patient cannot tolerate the side effects of oral treprostinil despite aggressive management, consider that the 2019 CHEST guidelines provide a weak recommendation for adding tadalafil to ambrisentan (not the reverse) 2. However, since your patient is already intolerant to ambrisentan, this is not applicable.
The key is assertive side effect management during the first 6 months to help the patient reach higher, more efficacious doses of Orenitram 3.